DBV Technologies S.A. American Depositary Shares (DBVT)

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

170

Website

www.dbv-technologies.com

Fundamentals

1-day range

$13.3$14.03

Market cap

$813.58M

P/E (trailing)

—

P/E (forward)

-25.34

EPS (trailing)

$-3.50

Dividend yield

—

Beta

-0.24

Avg. volume

308.2K

Forecasts

6 analyst ratings

DBV Technologies S.A. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• DBVT

  DBV Technologies S.A. American Depositary Shares

  $13.54

  ▼ 6.04%
  Market cap $813.58MP/E —
  $8.7$26.19
• SLDB

  Solid Biosciences Inc. Common Stock

  $9.78

  ▼ 3.46%
  Market cap $857.50MP/E —
  $3.79$11.45
• ALLO

  Allogene Therapeutics Inc. Common Stock

  $2.01

  ▼ 3.83%
  Market cap $679.95MP/E —
  $1.04$4.46
• SANA

  Sana Biotechnology Inc. Common Stock

  $3.93

  ▼ 3.91%
  Market cap $948.97MP/E —
  $2.61$6.55
• AGMB

  AgomAb Therapeutics NV American Depositary Shares

  $13.17

  ▼ 4.84%
  Market cap $664.85MP/E —
  $8.75$17.82
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $570.23MP/E —
  $14.39$39.53
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $551.51MP/E —
  $5.97$16.93

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

21.17M

Total value held

$424.99M

Institutional holders

70